Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature highlights translational pathophysiology with a tractable perioperative target (enteric glial connexin-43) and two high-impact clinical studies refining bedside decision-making: a large multicenter RCT showing no routine advantage of McGrath videolaryngoscopy over direct laryngoscopy for elective rapid-sequence intubation, and a validated AURIS clinical score that improves risk stratification for Candida auris candidaemia in colonized ICU patients. Together
Summary
This week’s anesthesiology literature highlights translational pathophysiology with a tractable perioperative target (enteric glial connexin-43) and two high-impact clinical studies refining bedside decision-making: a large multicenter RCT showing no routine advantage of McGrath videolaryngoscopy over direct laryngoscopy for elective rapid-sequence intubation, and a validated AURIS clinical score that improves risk stratification for Candida auris candidaemia in colonized ICU patients. Together these papers push forward actionable biomarker-directed perioperative interventions, evidence-based device selection in airway management, and practical infection-risk tools that can alter stewardship and empiric therapy decisions.
Selected Articles
1. Glial Connexin-43 is a pathogenic mechanism promoting gut inflammation after postsurgical intestinal manipulation with potential relevance to humans.
This mechanistic translational study demonstrates that enteric glial connexin-43 (Cx43) is highly expressed and upregulated after surgical intestinal manipulation, driving enteric gliosis, immune activation, inflammation, and enteric neuropathy that underpin postoperative ileus (POI). Glial-specific genetic deletion and a peptide inhibitor (43Gap26) attenuated pro-inflammatory signaling and POI features in mice, with supportive expression patterns in human surgical tissue and human enteric glial cells.
Impact: Identifies a tractable, cell-specific signaling node (enteric glial Cx43 hemichannels) that links surgical trauma to postoperative ileus across species, creating a clear translational path to peptide or small-molecule hemichannel modulators for perioperative organ-protection trials.
Clinical Implications: Supports development of selective Cx43 hemichannel modulators (e.g., 43Gap26 analogues) and perioperative trials with enteric gliosis/inflammation biomarkers to test prevention of postoperative ileus in high-risk abdominal surgery.
Key Findings
- Cx43 is the most highly expressed connexin in enteric glia in mice and humans and is upregulated after surgical trauma and in POI-related models.
- Glial-specific Cx43 deletion reduced glial reactivity, pro-inflammatory signaling, immune cell activation, and prevented enteric neuropathy in a mouse POI model.
- IL-1β opens Cx43 hemichannels in human enteric glial cells, increasing IL-6 and CCL2 release; the peptide inhibitor 43Gap26 blocks these responses.
- Patient intestinal surgical samples showed Cx43 upregulation paralleling mouse POI inflammation and enteric gliosis.
2. McGrath videolaryngoscopy versus direct laryngoscopy for rapid sequence intubation: A multicenter randomized clinical trial.
In a multicenter, patient‑blinded randomized trial of 400 adults undergoing elective rapid-sequence intubation for noncardiac surgery, McGrath videolaryngoscopy did not significantly improve glottic visualization (modified Cormack‑Lehane Grade 1 view) or first‑attempt intubation success compared with direct laryngoscopy, and median intubation time was modestly longer with McGrath. Airway complications were rare and similar between groups.
Impact: A large, well-conducted RCT that challenges the assumption of universal superiority of videolaryngoscopy in routine elective RSI and directly informs device-selection policies and training priorities in airway management.
Clinical Implications: For routine elective RSI in low‑risk populations, direct laryngoscopy remains an appropriate first‑line approach; reserve McGrath videolaryngoscopy for predicted or encountered difficult airways rather than routine use.
Key Findings
- No significant difference in Grade 1 modified Cormack‑Lehane view (46.6% VL vs 42.3% DL; OR 1.24; P=0.26).
- First‑attempt intubation success similar (86.5% VL vs 87.6% DL; P=0.76).
- Median time to intubation modestly longer with McGrath (35 s vs 30 s; HR 1.27; P=0.016).
3. Development and validation of the AURIS score for predicting candidaemia in Candidozyma auris-colonised patients in the intensive care unit: a bicentric retrospective cohort study.
In a bicentric retrospective ICU cohort (n=422 C. auris–colonized patients pooled), the AURIS four‑variable score (total parenteral nutrition, prior antifungal therapy, multifocal colonization, urinary isolation) achieved an AUC of 0.81 and outperformed the Candida score (AUC 0.75). At a 28% threshold, sensitivity was 0.72, specificity 0.84, and NPV 0.94, supporting its role to de‑escalate empiric antifungal therapy in low‑risk colonized patients.
Impact: Provides a validated, pragmatic bedside prediction tool for a high‑consequence, multidrug‑resistant ICU pathogen where prior scores underperform—directly actionable for antifungal stewardship and resource prioritization.
Clinical Implications: In C. auris–colonized ICU patients, apply the AURIS score to stratify candidemia risk: consider withholding or de‑escalating empiric antifungal therapy in low‑risk patients (high NPV), and prioritize diagnostics/treatment for high‑risk profiles (e.g., patients on TPN or with multifocal colonization).
Key Findings
- Four predictors retained: TPN, prior antifungal therapy, multifocal colonization, urinary isolation.
- AURIS discrimination AUC 0.81, outperforming Candida score (AUC 0.75; p=0.0003).
- At 28% threshold: sensitivity 0.72, specificity 0.84, negative predictive value 0.94.